

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8256452

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
AQUESTIVE THERAPEUTICS, INC.	11/01/2023

RECEIVING PARTY DATA

Name:	U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
Street Address:	ONE FEDERAL STREET, 3RD FLOOR
City:	BOSTON
State/Country:	MASSACHUSETTS
Postal Code:	02110

PROPERTY NUMBERS Total: 76

Property Type	Number
Patent Number:	7357891
Patent Number:	8603514
Patent Number:	7425292
Patent Number:	8017150
Patent Number:	7666337
Patent Number:	8765167
Patent Number:	7972618
Patent Number:	7910641
Patent Number:	8393255
Patent Number:	9150341
Patent Number:	8568777
Patent Number:	8298583
Patent Number:	8663696
Patent Number:	8282954
Patent Number:	9095577
Patent Number:	9095495
Patent Number:	8577488
Patent Number:	11129799
Patent Number:	8956685
Patent Number:	8936825

PATENT

Property Type	Number
Patent Number:	9561191
Patent Number:	9149959
Patent Number:	10272607
Patent Number:	10940626
Patent Number:	9346601
Patent Number:	9771173
Patent Number:	10464739
Patent Number:	10947033
Patent Number:	8241661
Patent Number:	8617589
Patent Number:	9511033
Patent Number:	9303918
Patent Number:	10034833
Patent Number:	11541002
Patent Number:	9474687
Patent Number:	10821074
Patent Number:	11191737
Patent Number:	11273131
Application Number:	17462132
Application Number:	17489128
Application Number:	16447107
Application Number:	17989307
Application Number:	18091556
Application Number:	17691107
Application Number:	17549219
Application Number:	17576923
Application Number:	17835442
Application Number:	63352098
Application Number:	63359424
Application Number:	17098324
Application Number:	16143036
Application Number:	17031207
Application Number:	15791249
Application Number:	16143821
Application Number:	16143678
Application Number:	17086409
Application Number:	18154428
Application Number:	17973345

Property Type	Number
Application Number:	17971282
Application Number:	63409991
Application Number:	18296790
Application Number:	63505014
Application Number:	18334986
Application Number:	63514743
PCT Number:	US2022019654
PCT Number:	US2022012633
PCT Number:	US2020058357
PCT Number:	US2020060464
PCT Number:	US2017031170
PCT Number:	US2017031167
PCT Number:	US2018052927
PCT Number:	US2018053042
PCT Number:	US2018053026
PCT Number:	US2022047741
PCT Number:	US2022047456
PCT Number:	US2023068449

CORRESPONDENCE DATA

Fax Number: (858)509-4010

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 8585094071

Email: michelle.mehok@pillsburylaw.com, sandra.edge@pillsburylaw.com, docket_ip@pillsburylaw.com

Correspondent Name: MICHELLE L. MEHOK

Address Line 1: 11682 EL CAMINO REAL, SUITE 200

Address Line 4: SAN DIEGO, CALIFORNIA 92130

ATTORNEY DOCKET NUMBER: 258340-0000857

NAME OF SUBMITTER: MICHELLE L. MEHOK

SIGNATURE: /michelle mehok/

DATE SIGNED: 11/02/2023

Total Attachments: 18

- source=11. Aquestive - Patent Collateral Agreement#page1.tif
- source=11. Aquestive - Patent Collateral Agreement#page2.tif
- source=11. Aquestive - Patent Collateral Agreement#page3.tif
- source=11. Aquestive - Patent Collateral Agreement#page4.tif
- source=11. Aquestive - Patent Collateral Agreement#page5.tif
- source=11. Aquestive - Patent Collateral Agreement#page6.tif
- source=11. Aquestive - Patent Collateral Agreement#page7.tif

source=11. Aquestive - Patent Collateral Agreement#page8.tif
source=11. Aquestive - Patent Collateral Agreement#page9.tif
source=11. Aquestive - Patent Collateral Agreement#page10.tif
source=11. Aquestive - Patent Collateral Agreement#page11.tif
source=11. Aquestive - Patent Collateral Agreement#page12.tif
source=11. Aquestive - Patent Collateral Agreement#page13.tif
source=11. Aquestive - Patent Collateral Agreement#page14.tif
source=11. Aquestive - Patent Collateral Agreement#page15.tif
source=11. Aquestive - Patent Collateral Agreement#page16.tif
source=11. Aquestive - Patent Collateral Agreement#page17.tif
source=11. Aquestive - Patent Collateral Agreement#page18.tif

PATENT COLLATERAL AGREEMENT

This **PATENT COLLATERAL AGREEMENT** (“Agreement”) is dated as of November 1, 2023, by and among **AQUESTIVE THERAPEUTICS, INC.**, a Delaware corporation with an address at 30 Technology Drive, Warren, New Jersey 07059 (the “Grantor”), and **U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION**, in its capacity as collateral agent for the Secured Parties (as defined below) with the address listed below (and its successors under the Indenture, in such capacity, the “Collateral Agent”).

PRELIMINARY STATEMENT

WHEREAS, the Grantor has entered into that certain Indenture dated as of the date hereof (as amended, extended, renewed, restated, supplemented, waived or otherwise modified from time to time, the “Indenture”) with the Collateral Agent and U.S. Bank Trust Company, National Association, in its capacity as Trustee having an address at One Federal Street, 3rd Floor, Boston, Massachusetts 02110 (and its successors under the Indenture (as defined below), in such capacity, the “Trustee”);

WHEREAS, as a condition to the issuance by the Issuer of its 13.5% Senior Secured Notes due 2028, the Grantor has entered into that certain Collateral Agreement dated as of the date hereof (as may be amended, extended, renewed, restated, supplemented, waived or otherwise modified from time to time, the “Collateral Agreement”); and

WHEREAS, pursuant to the terms of the Collateral Agreement, the Grantor has agreed to grant to the Collateral Agent, for the benefit of the Secured Parties (as defined in the Collateral Agreement), a continuing security interest in and lien on, the Grantor’s right, title and interest in and to all present and future copyrights, patents, trademarks, and related licenses and rights for the benefit of the Secured Parties; and

WHEREAS, pursuant to the Collateral Agreement, the Grantor is required to execute and deliver to the Collateral Agent this Agreement.

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor hereby agrees as follows:

I. DEFINED TERMS. All capitalized terms used but not otherwise defined herein have the meanings given to them in the Collateral Agreement.

II. GRANT OF SECURITY INTEREST IN PATENT COLLATERAL. The Grantor hereby grants to the Collateral Agent, for the benefit of the Secured Parties, on the terms set forth in and subject to the Collateral Agreement, a continuing first-priority lien and security interest (subject to Permitted Liens) in all of the Grantor’s right, title and interest in, to and under the following, whether presently existing or hereafter created or acquired (collectively, the “Patent Collateral”):

A. all of its patent applications, patents and intellectual property licenses to which it is a party including those set forth in Schedule I hereto (the “Patents”);

B. all divisionals, continuations, continuations in part, reissues, reexaminations, or extensions of the foregoing; and

C. all products and proceeds of the Patents, including any claim by the Grantor against third parties for past, present or future (i) infringement of any Patents or any Patents exclusively licensed under any intellectual property license, including the right to receive any damages, or (ii) right to receive license fees, royalties and other compensation under any intellectual property license;

provided, however, that, notwithstanding anything herein to the contrary, the Patent Collateral shall not include, and the lien and security interest granted in this Agreement shall not attach to, the Excluded Assets of the type described in clause (i) of the definition thereof.

III. SECURITY FOR OBLIGATIONS. The grant of a lien and security interest in the Patent Collateral by the Grantor pursuant to this Agreement secures prompt payment to the Secured Parties of the Obligations. This Agreement and the lien and security interest created hereby secures the payment and performance of the Obligations, whether now existing or arising hereafter. Without limiting the generality of the foregoing, this Agreement secures the payment of all amounts which constitute part of the Obligations (as defined in the Collateral Agreement) and would be owed by the Grantor to the Secured Parties, whether or not they are unenforceable or not allowable due to the existence of a proceeding commenced by or against the Grantor under any provision of the Bankruptcy Code (or under any other applicable foreign bankruptcy, insolvency, receivership or similar law) or under any other state or federal bankruptcy or insolvency law, assignments for the benefit of creditors, formal or informal moratoria, compositions, extensions generally with creditors, or proceedings seeking reorganization, arrangement, or other similar relief.

IV. COLLATERAL AGREEMENT. The lien and security interest granted pursuant to this Agreement is granted in conjunction with the lien and security interests granted to the Collateral Agent pursuant to the Collateral Agreement. The Grantor hereby acknowledges and affirms that the rights and remedies of the Collateral Agent with respect to the lien and security interest in the Patent Collateral made and granted hereby are more fully set forth in the Collateral Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. To the extent there is any inconsistency between this Agreement and the Collateral Agreement, the Collateral Agreement shall control.

V. AUTHORIZATION TO SUPPLEMENT. The Grantor hereby authorizes the Collateral Agent to modify this Agreement by amending Schedule I to include any new patent rights of the Grantor in accordance with the provisions of the Collateral Agreement; provided, that, the Collateral Agent shall provide prior written notice to the Grantor of any such amendment or modification, including a copy of the proposed amendment or modification to Schedule I. Notwithstanding the foregoing, no failure to so modify this Agreement or amend Schedule I or provide notice to the Grantor of same shall in any way affect, invalidate or detract

from the Collateral Agent's continuing security interest in all Collateral, whether or not listed on Schedule I.

VI. LIMITATION BY LAW; SEVERABILITY OF PROVISIONS. All rights, remedies and powers provided in this Agreement may be exercised only to the extent that the exercise thereof does not violate any applicable provision of law, and all the provisions of this Agreement are intended to be subject to all applicable mandatory provisions of law that may be controlling and to be limited to the extent necessary so that they shall not render this Agreement invalid, unenforceable or not entitled to be recorded or registered, in whole or in part. The illegality or unenforceability of any provision of this Agreement or any instrument or agreement required hereunder shall not in any way affect or impair the legality or enforceability of the remaining provisions of this Agreement or any instrument or agreement required hereunder.

VII. BINDING EFFECT. The provisions of this Agreement shall be binding upon and inure to the benefit of the respective representatives, successors, and permitted assigns of the parties hereto; provided, however, the Grantor shall not assign or delegate any of its rights or duties under this Agreement without the prior written consent of the Collateral Agent (other than pursuant to a transaction permitted under the Indenture), and any attempted assignment without such consent shall be null and void. The rights and benefits of the Collateral Agent hereunder shall, if such Persons so agree, inure to any party acquiring any interest in the Obligations or any part thereof in accordance with the terms hereof or of the Collateral Agreement.

VIII. CAPTIONS. The captions contained in this Agreement are for convenience of reference only, are without substantive meaning and should not be construed to modify, enlarge, or restrict any provision.

IX. TERMINATION AND RELEASE. This Agreement shall terminate in accordance with the Collateral Agreement.

X. ENTIRE AGREEMENT. This Agreement, together with the Collateral Agreement, other Indenture Documents (as defined in the Indenture) and the other Security Documents, embodies the entire agreement and understanding between the Grantor and the Collateral Agent relating to the Patent Collateral and supersedes all prior agreements and understandings between the Grantor and the Collateral Agent relating to the Patent Collateral.

XI. COUNTERPARTS. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one agreement, and any of the parties hereto may execute this Agreement by signing any such counterpart, and a copy of any such counterpart shall be valid as an original.

XII. AMENDMENTS. Neither this Agreement nor any provision hereof may be waived, amended or modified except pursuant to an agreement or agreements in writing entered into by the Collateral Agent and the Grantor with respect to which such waiver, amendment or modification is to apply, subject to any consent that may be required in accordance with the Collateral Agreement.

XIII. GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW (OTHER THAN SECTIONS 5-1401 AND 5-1402 OF THE NEW YORK GENERAL OBLIGATIONS LAW) EXCEPT TO THE EXTENT THAT LOCAL LAW GOVERNS THE CREATION, PERFECTION, PRIORITY OR ENFORCEMENT OF SECURITY INTERESTS.

XIV. CONCERNING THE COLLATERAL AGENT. U.S. Bank Trust Company, National Association is entering into this Agreement solely in its capacity as Collateral Agent under the Indenture and not in its individual capacity. In acting hereunder, the Collateral Agent shall be entitled to all of the rights, privileges, indemnities and immunities set forth in the Indenture and the Collateral Agreement as if such rights, privileges, indemnities and immunities were set forth herein.

[signature page follows]

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

AQUESTIVE THERAPEUTICS, INC.

By: 

Name: Daniel Barber


Title: Chief Executive Officer

{Signature Page to the Patent Collateral Agreement}

PATENT
REEL: 065446 FRAME: 0502

ACCEPTED AND ACKNOWLEDGED BY:

**U.S. BANK TRUST COMPANY, NATIONAL
ASSOCIATION**, as Collateral Agent
One Federal Street, 3rd Floor
Boston, Massachusetts 02110

By:  _____
Name: Alison D.B. Nadeau _____
Vice President
Title: _____

{Signature Page to the Patent Collateral Agreement}

PATENT
REEL: 065446 FRAME: 0503

Schedule 1
to
PATENT COLLATERAL AGREEMENT

A	B	C	D	E	F	G	H	I	J	K	L	
HA&B Ref	Appln. No.	Appln. Date	Title	Status	Substatus	Country	Pat. No.	Issue Date	Publn. No.	Publn. Date	Exp. Date	
1	1199-26 PCT/EPO/DIV II	5/28/2004	POLYETHYLENE OXIDE BASED FILMS AND DRUG DELIVERY SYSTEMS MADE THEREFROM	Filed - (F)		European Patent Convention - (EP)			3210601	8/30/2017		
2	1199-82 A/Argentina	8/6/2010	Sublingual And Buccal Film Compositions: Process, Method Of Treatment	Filed - (F)		Argentina - (AR)			77803	9/12/2011		
3	1199-82 A/Pakistan	8/5/2010	Sublingual And Buccal Film Compositions	Filed - (F)		Pakistan - (PK)						
4	1199-112 CON	8/31/2021	DUAL LANE COATING	Filed - (F)		United States - (US)			2022-0054426	2/24/2022		
5	1199-117 PCT/CHINA/DIV	9/21/2011	METHOD AND SYSTEM FOR FORMING A PHARMACEUTICAL PRODUCT DIRECTLY ONTO A PACKAGING SURFACE	Filed - (F)		China P.R. - (CN)						
6	1199-119 PCT/EPO/DIV	10/21/2011	MANUFACTURING OF SMALL FILM STRIPS	Filed - (F)	Allowed - (A)	European Patent Convention - (EP)			3566841	11/13/2019		
7	1199-130 PCT/EPO	3/14/2014	REDUCTION IN STRESS CRACKING OF FILMS	Filed - (F)		European Patent Convention - (EP)			2968058	1/20/2016		
8	1199-141 PCT/EPO/DIV	5/4/2012	BIOCOMPATIBLE FILM WITH VARIABLE GROSS-SECTIONAL PROPERTIES	Filed - (F)		European Patent Convention - (EP)			3381450	10/3/2018		
9	1199-148 PCT/CANADA	3/14/2014	SUBLINGUAL AND BUCCAL FILM COMPOSITIONS	Filed - (F)	Allowed - (A)	Canada - (CA)						
10	1199-151 PCT/CANADA	12/9/2015	LINEAR POLYSACCHARIDE BASED FILM PRODUCTS	Filed - (F)		European Patent Convention - (EP)						
11	1199-151 PCT/CANADA	12/9/2015	LINEAR POLYSACCHARIDE BASED FILM PRODUCTS	Filed - (F)		European Patent Convention - (EP)						
12	1199-151 PCT/EPO	12/9/2015	LINEAR POLYSACCHARIDE BASED FILM PRODUCTS	Filed - (F)		Republic of Korea - (KR)			3229778	10/18/2017		
13	1199-151 PCT/SOUTH-KOREA	12/9/2015	LINEAR POLYSACCHARIDE BASED FILM PRODUCTS	Filed - (F)		United States - (US)						
14	1199-151 PCT/US/CZ/C	9/29/2021	LINEAR POLYSACCHARIDE BASED FILM PRODUCTS	Filed - (F)	Allowed - (A)	United States - (US)			2019-0388802	12/26/2019		
15	1199-198	6/20/2019	SYSTEM AND METHOD FOR MARKING PERSONALIZED PHARMACEUTICAL ACTIVES	Filed - (F)		United States - (US)						
16	1199-198 PCT/AU	6/20/2019	SYSTEM AND METHOD FOR MARKING PERSONALIZED PHARMACEUTICAL ACTIVES	Filed - (F)		Australia - (AU)						
17	1199-198 PCT/BR	6/20/2019	SYSTEM AND METHOD FOR MARKING PERSONALIZED PHARMACEUTICAL ACTIVES	Filed - (F)		Brazil - (BR)			BR112021001738 0	6/29/2021		
18	1199-198 PCT/CA	6/20/2019	SYSTEM AND METHOD FOR MARKING PERSONALIZED PHARMACEUTICAL ACTIVES	Filed - (F)		Canada - (CA)						
19	1199-198 PCT/CN	6/20/2019	SYSTEM AND METHOD FOR MARKING PERSONALIZED PHARMACEUTICAL ACTIVES	Filed - (F)		China P.R. - (CN)			CN 112585690 A	3/20/2021		
20	1199-198 PCT/EPO	6/20/2019	SYSTEM AND METHOD FOR MARKING PERSONALIZED PHARMACEUTICAL ACTIVES	Filed - (F)		European Patent Convention - (EP)			3811371	4/28/2021		
21	1199-198 PCT/JP	6/20/2019	SYSTEM AND METHOD FOR MARKING PERSONALIZED PHARMACEUTICAL ACTIVES	Filed - (F)		Japan - (JP)						
22	1199-205 CON	11/17/2022	ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES	Filed - (F)		United States - (US)			2023-0149304	5/18/2023		
23	1199-205 CON2	12/30/2022	ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES	Filed - (F)		United States - (US)			2023-0145752	5/11/2023		
24	1199-205 PCT/BR	9/5/2019	ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES	Filed - (F)		Brazil - (BR)			BR112021004053 6	5/25/2021		
25	1199-205 PCT/CA	9/5/2019	ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES	Filed - (F)		Canada - (CA)						
26	1199-205 PCT/CN	9/5/2019	ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES	Filed - (F)		China P.R. - (CN)			112955124 A	6/11/2021		
27	1199-205 PCT/EPO	9/5/2019	ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES	Filed - (F)		European Patent Convention - (EP)			3846778	7/14/2021		
28	1199-205 PCT/JP	9/5/2019	ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES	Filed - (F)		Japan - (JP)			2021-536466	12/27/2021		
29	1199-206	3/9/2022	BIOCOMPARABLE PROFILES	Filed - (F)		United States - (US)			2022-0347117	11/3/2022		
30	1199-206 PCT	3/9/2022	BIOCOMPARABLE PROFILES	Filed - (F)		Patent Cooperation Treaty - (WO)			2022/192476	9/15/2022		
31	Homogen LLP Responsible Matters											
32	AQU-014USCIPCPCIP	12/13/2021	ENHANCED DELIVERY ENHANCEMENT AND PRODRUG COMPOSITIONS	Filed - (F)		United States - (US)			20220160657	5/26/2022		
33	AQU-041US	1/15/2022	PRODRUG COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		United States - (US)			20220233471	7/28/2022		
34	AQU-041WO	1/15/2022	PRODRUG COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		Patent Cooperation Treaty - (WO)						
35	AQU-039WOCA	4/27/2022	PRODRUG COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		Canada - (CA)						

A	B	C	D	E	F	G	H	I	J	K	L
App. No.	App. No.	App. No.	Title	Status	Substatus	Country	Pat. No.	Issue Date	Publn. No.	Publn. Date	Exp. Date
36	AQU-039W01L	292487	PRODRUG COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		Israel - (IL)					
37	AQU-039W0JP	2022-525359	PRODRUG COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		Japan - (JP)					
38	AQU-039W0MK	MX/6/2022/004983	PRODRUG COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		Mexico - (MX)					
39	AQU-040W0CA	3,159,382	MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		Canada - (CA)					
40	AQU-014USC2	17/835,442	ENHANCED DELIVERY EPINEPHRINE COMPOSITIONS	Filed - (F)		United States - (US)					
41	AQU-044PR	63/352,098	ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS	Filed - (F)		United States - (US)					
42	AQU-044PR2	63/359,424	ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS	Filed - (F)		United States - (US)					
43	AQU-039W0BR	BR112022008294.0	PRODRUG COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		Brazil - (BR)		11/2022008294.0		07/26/2022	
44	AQU-039W0CN	202080089502.X	PRODRUG COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		China P.R. - (CN)					
45	AQU-039W0ZA	2022/04995	PRODRUG COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		South Africa					
46	AQU-039W0AU	2020373100.0	PRODRUG COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		Australia - (AU)					
47	AQU-039W0KR	10-2022-7018616	PRODRUG COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		Korea - (KR)					
48	AQU-040W0BR	BR112022008784.5	MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		Brazil - (BR)		11/2022008784.5		7/26/2022	
49	AQU-040W0CN	202080092463.9	MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		China P.R. - (CN)					
50	AQU-040US	17/098,324	MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		United States - (US)		202110145731		5/20/2021	
51	AQU-040W0JP	2022-528074	MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		Japan - (JP)					
52	AQU-040W0KR	10-2022-7020143	MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		Korea - (KR)					
53	AQU-039W0EP	208086909.0	PRODRUG COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		European Patent Convention - (EP)		4051235		09/07/2022	
54	AQU-040W0EP	208207111.8	MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		European Patent Convention - (EP)		2,771,089		2/10/2011	
55	AQU-027USW0CA	2,771,089	SUBLINGUAL AND BUCCAL FILM COMPOSITIONS	Filed - (F)		Canada - (CA)		3326612		5/30/2018	
56	AQU-027US0FD1	18150094.3	SUBLINGUAL AND BUCCAL FILM COMPOSITIONS	Filed - (F)		European Patent Convention - (EP)		2511		02/19/2019	
57	AQU-013W0BR	BR112018072467.0	PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION	Filed - (F)		Brazil - (BR)		3022297		11/09/2017	
58	AQU-013W0CA	3,022,297	PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION	Filed - (F)		Canada - (CA)		109310647		02/05/2019	
59	AQU-013W0CN	201180037588.X	PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION	Filed - (F)		China P.R. - (CN)		3452024		03/13/2019	
60	AQU-013W0EP	17723617.1	PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION	Filed - (F)		European Patent Convention - (EP)		11/2019		03/15/2019	
61	AQU-013W0IN	201817045293	PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION	Filed - (F)		India - (IN)					
62	AQU-013W0IL	262751	PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION	Filed - (F)		Israel - (IL)					
63	AQU-013W0JP	2018-558225	PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION	Filed - (F)		Japan - (JP)		2019-519488		07/11/2019	
64	AQU-013W0KR	10-2018-7035236	PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION	Filed - (F)		Korea - (KR)		10-2018-7035236		1/15/2019	
65	AQU-014W0BR	BR1120180725399.0	ENHANCED DELIVERY EPINEPHRINE COMPOSITIONS	Filed - (F)		Brazil - (BR)		2516		03/26/2019	
66	AQU-014W0CA	3,022,240	ENHANCED DELIVERY EPINEPHRINE COMPOSITIONS	Filed - (F)		Canada - (CA)		109310646		11/09/2017	
67	AQU-014W0CN	201780037587.5	ENHANCED DELIVERY EPINEPHRINE COMPOSITIONS	Filed - (F)		China P.R. - (CN)		3452023		02/05/2019	
68	AQU-014W0EP	17723616.3	ENHANCED DELIVERY EPINEPHRINE COMPOSITIONS	Filed - (F)		European Patent Convention - (EP)		11/2019		03/13/2019	
69	AQU-014W0IN	201817045308	ENHANCED DELIVERY EPINEPHRINE COMPOSITIONS	Filed - (F)		India - (IN)		2019-519487		07/11/2019	
70	AQU-014W0JP	2018-558224	ENHANCED DELIVERY EPINEPHRINE COMPOSITIONS	Filed - (F)		Japan - (JP)		10-2018-7035240		10-2018-7035240	
71	AQU-014W0KR	10-2018-7035240	ENHANCED DELIVERY EPINEPHRINE COMPOSITIONS	Filed - (F)		Korea - (KR)		2995		09/29/2020	
72	AQU-026W0BR	BR112020005875-0	DELIVERY PHARMACEUTICAL COMPOSITIONS INCLUDING PERMEATION ENHANCERS	Filed - (F)		Brazil - (BR)		3,076,751		04/04/2019	
73	AQU-026W0CA	3,076,751	DELIVERY PHARMACEUTICAL COMPOSITIONS INCLUDING PERMEATION ENHANCERS	Filed - (F)		Canada - (CA)		111148512		05/12/2020	
74	AQU-026W0CN	201880062678.9	DELIVERY PHARMACEUTICAL COMPOSITIONS INCLUDING PERMEATION ENHANCERS	Filed - (F)		China P.R. - (CN)		3667508		08/05/2020	
75	AQU-026W0EP	18786579.5	DELIVERY PHARMACEUTICAL COMPOSITIONS INCLUDING PERMEATION ENHANCERS	Filed - (F)		European Patent Convention - (EP)					

A	B	C	D	E	F	G	H	I	J	K	L
App. No.	App. No.	App. No.	Title	Status	Substatus	Country	Pat. No.	Issue Date	Publn. No.	Publn. Date	Exp. Date
1	AQU-026WMOIN	202017016904	DELIVERY PHARMACEUTICAL COMPOSITIONS INCLUDING PERMEATION ENHANCERS	Filed - (F)		India - (IN)			35/2020	08/28/2020	
76	AQU-026WMOIL	273477	DELIVERY PHARMACEUTICAL COMPOSITIONS INCLUDING PERMEATION ENHANCERS	Filed - (F)		Israel - (IL)			2020-535232	12/03/2020	
77	AQU-026WMOIP	2020-538776	DELIVERY PHARMACEUTICAL COMPOSITIONS INCLUDING PERMEATION ENHANCERS	Filed - (F)		Japan - (JP)			10-2020-0059269	05/28/2020	
78	AQU-026WOKR	10-2020-7011909	DELIVERY PHARMACEUTICAL COMPOSITIONS INCLUDING PERMEATION ENHANCERS	Filed - (F)		Korea - (KR)			2019-091281	03/28/2019	
79	AQU-026WUS	16/143,036	DELIVERY PHARMACEUTICAL COMPOSITIONS INCLUDING PERMEATION ENHANCERS	Filed - (F)		United States - (US)			US 2021-0244655 A1	08/12/2021	
80	AQU-027USC1C1C1	17/031,207	SUBLINGUAL AND BUCCAL FILM COMPOSITIONS	Filed - (F)		United States - (US)			2018-0104,95	4/19/2018	
81	AQU-014USC1C1C1C1	15/791,249	ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS	Filed - (F)		United States - (US)			112020005948.0	12/1/2020	
82	AQU-014USC1C1C1C1	BR11200005948.0	ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS	Filed - (F)		Brazil - (BR)			3,076,816	4/4/2019	
83	AQU-014USC1C1C1C1	3,076,816	ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS	Filed - (F)		Canada - (CA)			111465391	7/28/2020	
84	AQU-014USC1C1C1C1	201880063175.3	ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS	Filed - (F)		China P.R. - (CN)			3687510	8/5/2020	
85	AQU-014USC1C1C1C1	18786593.6	ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS	Filed - (F)		European Patent Convention - (EP)			35/2020	8/28/2020	
86	AQU-014USC1C1C1C1	202017016998	ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS	Filed - (F)		India - (IN)					
87	AQU-014USC1C1C1C1	273485	ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS	Filed - (F)		Israel - (IL)			2020-535162	12/3/2020	
88	AQU-014USC1C1C1C1	2020-517419	ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS	Filed - (F)		Japan - (JP)			10-2020-0060748	6/1/2020	
89	AQU-014USC1C1C1C1	10-2020-7012106	ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS	Filed - (F)		Korea - (KR)			2019-022023	01/24/2019	
90	AQU-014USC1C1C1C1	16/143,821	ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS	Filed - (F)		United States - (US)			296	10/06/2020	
91	AQU-023WOBK	BR112020005967.6	PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION	Filed - (F)		Brazil - (BR)			3,076,815	04/04/2019	
92	AQU-023WOCB	3,076,815	PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION	Filed - (F)		Canada - (CA)			111132670A	05/08/2020	
93	AQU-023WOCN	201880062717.5	PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION	Filed - (F)		China P.R. - (CN)			3687509	08/05/2020	
94	AQU-023WOCF	18786591.0	PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION	Filed - (F)		European Patent Convention - (EP)			35/2020	08/28/2020	
95	AQU-023WOCN	202017016905	PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION	Filed - (F)		India - (IN)					
96	AQU-023WOCIL	273479	PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION	Filed - (F)		Israel - (IL)			2020-535176	12/03/2020	
97	AQU-023WOCIP	2020-517586	PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION	Filed - (F)		Japan - (JP)			10-2020-0060457	05/29/2020	
98	AQU-023WOKR	10-2020-7012033	PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION	Filed - (F)		Korea - (KR)			2019-022022	1/24/2019	
99	AQU-023WUS	16/143,678	PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION	Filed - (F)		United States - (US)			US 2021-0128511 A1	5/6/2021	
100	AQU-039US	17/086,409	PRODRUG COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		United States - (US)			WO/2021/087359	5/6/2021	
101	AQU-039WMO	PCT/US2020/058337	PRODRUG COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		United States - (US)					
102	AQU-040US	17/098,324	MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		United States - (US)			WO/2021/097247	5/20/2021	
103	AQU-040WMO	PCT/US2020/060464	MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		United States - (US)					
104	AQU-014USC2	17/835,442	ENHANCED DELIVERY EPINEPHRINE COMPOSITIONS	Filed - (F)		United States - (US)			2017192923	11/9/2017	
105	AQU-013WMO	PCT/US2017/031167	ENHANCED DELIVERY EPINEPHRINE COMPOSITIONS	Filed - (F)		United States - (US)			2017192921	11/9/2017	
106	AQU-026WMO	PCT/US2018/052927	DELIVERY PHARMACEUTICAL COMPOSITIONS INCLUDING PERMEATION ENHANCERS	Filed - (F)		United States - (US)			2019067596	4/4/2019	
107	AQU-014USC1C1C1	9/27/2018	ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS	Filed - (F)		United States - (US)					
108	AQU-014USC1C1C1	9/27/2018	ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS	Filed - (F)		United States - (US)					
109	AQU-014USC1C1C1	9/27/2018	ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS	Filed - (F)		United States - (US)					

A	B	C	D	E	F	G	H	I	J	K	L
Issue Ref	Appln. No.	Appln. Date	Title	Status	Substatus	Country	Pat. No.	Issue Date	Publn. No.	Publn. Date	Exp. Date
110	AQU-023WO	PCT/US2018/053026	PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION	Filed - (F)		United States - (US) Patent Cooperation Treaty - (WO)			201967667	4/4/2019	
111	AQU-0141USC3	18/154,428	ENHANCED DELIVERY EPINEPHRINE COMPOSITIONS	Filed - (F)		United States - (US)					
112	AQU-014WQJPD1	2022.211123	ENHANCED DELIVERY EPINEPHRINE COMPOSITIONS	Filed - (F)		Japan - (JP)					
113	AQU-040US2	17/973,345	ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		United States - (US)					
114	AQU-040WQ2	PCT/US2022/047741	Oral and Nasal Compositions and Methods of Treatment	Filed - (F)		Patent Cooperation Treaty - (WO)					
115	AQU-042US	17/971,282	Pharmaceutical Compositions with Enhanced Stability Profiles	Filed - (F)		United States - (US)					
116	AQU-042WO	PCT/US2022/047456	Pharmaceutical Compositions with Enhanced Stability Profiles	Filed - (F)		Patent Cooperation Treaty - (WO)					
117	AQU-044PR3	63/409,991	Enhanced Delivery Epinephrine and Prodrug Compositions	Filed - (F)		United States - (US)					
118	AQU-013USQJPCF3	18/296,790	PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION	Filed - (F)		United States - (US)					
119	AQU-044PR4	63/505,014	ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS	Filed - (F)		United States - (US)					
120	AQU-044US	18/334,986	ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS	Filed - (F)		United States - (US)					
121	AQU-044WO	PCT/US2023/068449	ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS	Filed - (F)		Patent Cooperation Treaty - (WO)					
122	AQU-013WQJPD1	2023-104610	PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION	Filed - (F)		Japan - (JP)					
123	AQU-041WQBR	112023014015-3	PRODRUG COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		Brazil - (BR)					
124	AQU-041WQCA	7/13/2023	PRODRUG COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		Canada - (CA)					
125	AQU-041WQJP	2023.542915	PRODRUG COMPOSITIONS AND METHODS OF TREATMENT	Filed - (F)		Japan - (JP)					
126	AQU-045FR	63/514,743	ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS	Filed - (F)		United States - (US)					

Aggressive Therapeutics - Patents

A	B	C	D	E	F	G	H	I	J	K	L
H&B Ref	Country	Notes	Status	Exp. Date	Title	Appln. No.	Appln. Date	Pat. No.	Issue Date	Publn. No.	Publn. Date
1	A										
2	1199-4-B	US	United States - (US)	6/18/2024	Process for Making An Ingestible Film	10/768,809	1/30/2004	7,387,593*	4/15/2008	2004-023896A1	11/23/2004
3	1199-4-B C/P/ACE	US	United States - (US)	4/3/2024	Uniform Films For Rapid Dissolve Form	11/775,484	7/10/2007	8,603,514*	12/10/2013	2008-0044454A1	2/21/2008
4	1199-4-B/PCT/Kenada	CA	Canada - (CA)	1/30/2024	Heterogeneity And Drug Delivery Systems Made	2,514,897	1/30/2004	2,514,897	8/28/2012	C2514897	8/12/2004
5	1199-4-B/PCT/China	CN	China P.R. - (CN)	1/29/2024	The Film With Non-Self Aggregating Uniform	200460088385.6	1/30/2004	ZL200480003193	12/29/2007	CN1754443A	4/28/2006
6	1199-4-B/PCT/EPO/Denmark	DK	Denmark - (DK)	1/30/2024	The Film With Non-Self Aggregating Uniform	0407004.0	1/30/2004	1587504	4/18/2012	1587504	10/26/2005
7	1199-4-B/PCT/EPO/France	FR	France - (FR)	1/30/2024	The Film With Non-Self Aggregating Uniform	0407004.0	1/30/2004	1587504	4/18/2012	1587504	10/26/2005
8	1199-4-B/PCT/EPO/Germany	DE	Germany - (DE)	1/30/2024	The Film With Non-Self Aggregating Uniform	0407004.0	1/30/2004	1587504	4/18/2012	E02004037401.6	10/26/2005
9	1199-4-B/PCT/EPO/Hungary	HU	Hungary - (HU)	1/30/2024	The Film With Non-Self Aggregating Uniform	0407004.0	1/30/2004	1587504	4/18/2012	1587504	10/26/2005
10	1199-4-B/PCT/EPO/Ireland	IE	Ireland - (IE)	1/30/2024	The Film With Non-Self Aggregating Uniform	0407004.0	1/30/2004	1587504	4/18/2012	1587504	10/26/2005
11	1199-4-B/PCT/EPO/Switzerland	CH	Switzerland - (CH)	1/30/2024	The Film With Non-Self Aggregating Uniform	0407004.0	1/30/2004	1587504	4/18/2012	1587504	10/26/2005
12	1199-4-B/PCT/EPO/UK	GB	Great Britain - (GB)	1/29/2024	The Film With Non-Self Aggregating Uniform	0407004.0	1/30/2004	1587504	4/18/2012	1587504	10/26/2005
13	1199-4-B/PCT/India	IN	India - (IN)	1/30/2024	The Film With Non-Self Aggregating Uniform	1550/KUMF/2005	1/30/2004	228056	1/28/2009	1550/KUMF/2005	9/15/2006
14	1199-4-B/PCT/Japan	JP	Japan - (JP)	1/30/2024	Heterogeneity And Drug Delivery Systems Made	2006-503172	1/30/2004	5169888	12/18/2012	2006-516984	7/6/2006
15	1199-4-B/PCT/Japan/Div	JP	Japan - (JP)	1/30/2024	The Film With Non-Self Aggregating Uniform	2011-000174	1/30/2004	573801	4/3/2015	2011-68869	4/7/2011
16	1199-4-B/PCT/JAPAN/Div III	JP	Japan - (JP)	1/30/2024	The Film With Non-Self Aggregating Uniform	2015-038002	1/30/2004	6109866	3/17/2017		
17	1199-4-R/CE II	US	United States - (US)	10/28/2023	THIN FILM WITH SELF-AGGREGATING UNIFORM	10/074,272	2/14/2002	7,425,292*	9/16/2008	2003-010749A1	6/12/2003
18	1199-13 PCT/Kanada	CA	Canada - (CA)	7/22/2023**	PACKAGING AND DISPENSING OF RAPID DISSOLVE	2,505,796	7/22/2003	CN2,505,796	1/29/2004	2,505,796	1/3/2012
19	1199-13 PCT/China	CN	China P.R. - (CN)	7/21/2023**	Packaging And Dispensing Of Rapid Dissolve Dosage Form	03822424.0	7/22/2003	CN1747656A	3/15/2006	ZL03822424.0	5/4/2011
20	1199-13 PCT/EPO/France	FR	France - (FR)	7/22/2023**	PACKAGING AND DISPENSING OF RAPID DISSOLVE	03748966.3	7/22/2003			1543903	5/20/2015
21	1199-13 PCT/EPO/Germany	DE	Germany - (DE)	7/22/2023**	PACKAGING AND DISPENSING OF RAPID DISSOLVE	03748966.3	7/22/2003	62347639.2		1543903	5/20/2015
22	1199-13 PCT/EPO/SWITZERLAND	CH	Switzerland - (CH)	7/22/2023**	PACKAGING AND DISPENSING OF RAPID DISSOLVE	03748966.3	7/22/2003			1543903	5/20/2015

A	B	C	D	E	F	G	H	I	J	K	L
Int. Ref.	Country	Notes	Status	Exp. Date	Title	Appl. No.	Appl. Date	Pat. No.	Issue Date	Publ. No.	Publ. Date
1	US		Granted - (G)	7/22/2023**	PACKAGING AND DISPENSING OF RAPID DISSOLVE DOSE-AGE FORMS	03748966.3	7/22/2003	1543903	5/20/2003	5/20/2003	5/20/2003
23	JP	Patent maintained in amended form following appeal proceedings	Granted - (G)	1/25/2028	Polymer Based Films and Drug Delivery Systems Made Therefrom	2009-549385	1/25/2008	5358905	5/9/2014	2010-518241	7/2/2014
24	JP		Granted - (G)	10/20/2023	Polyethylene Oxide-based Films and Drug Delivery Systems Made Therefrom	121/07/389	4/22/2008	8,017,150*	9/13/2011	2008-0266809	10/29/2008
25	US		Granted - (G)	5/29/2024	Polyethylene Oxide-based Films and Drug Delivery Systems Made Therefrom	200439243	5/28/2004	200439243	6/3/2010	2004-319243	1/12/2006
26	AU		Granted - (G)	5/29/2024	Polyethylene Oxide-based Films and Drug Delivery Systems Made Therefrom	2544,776	5/28/2004	2,544,776	4/15/2014	CAS44776	3/28/2006
27	CA		Granted - (G)	5/27/2024	Polyethylene Oxide-based Films and Drug Delivery Systems Made Therefrom	20046001796e.9	5/28/2004	CN1812773A	6/27/2012	CN 1812773A	8/2/2006
28	CN		Granted - (G)	5/29/2024	Polyethylene Oxide-based Films and Drug Delivery Systems Made Therefrom	2006-535223	5/28/2004	4793962	8/5/2011	2007-502052	1/11/2007
29	JP		Granted - (G)	5/29/2024	Polyethylene Oxide-based Films and Drug Delivery Systems Made Therefrom	PA672005/012815	5/28/2004	328804	3/18/2015		3/13/2012
30	MX		Granted - (G)	6/21/2024	Polyethylene Oxide-based Films and Drug Delivery Systems Made Therefrom	10/856,176	5/28/2004	7,666,337*	2/23/2010	2005-0037055A1	2/17/2005
31	US		Granted - (G)	2/6/2026	Polyethylene Oxide-based Films and Drug Delivery Systems Made Therefrom	95/002,171	9/10/2012	7,666,337	5/11/2016		
32	US	Inter partes Reexamination Certificate issued on 5/11/2016, US 7,666,337 C1 (Reexamination Request No. 95/002,171, 9/10/2012)	Granted - (G)	2/6/2026							
33	US	Prevalled in IPR and Appeal challenges	Granted - (G)	2/29/2024	Uniform Films For Rapid-Dissolve Dosage Form Incorporating Anti-Floating Compositions	112517,282	9/6/2006	8,785,167*	7/1/2014	2007-0122455A1	5/31/2007
34	CA		Granted - (G)	9/28/2025	MULTI-LAYER FILMS HAVING UNIFORM CONTENT	2,381,851	9/28/2005	2,581,851	11/1/2016	CA2381851	4/13/2006
35	DK		Granted - (G)	9/28/2025	MULTI-LAYER FILMS HAVING UNIFORM CONTENT	05803856.3	9/28/2005	1799453	9/5/2012	1799453	6/27/2007
36	FR		Granted - (G)	9/28/2025	MULTI-LAYER FILMS HAVING UNIFORM CONTENT	05803856.3	9/28/2005	1799453	9/5/2012	1799453	6/27/2007
37	DE		Granted - (G)	9/28/2025	MULTI-LAYER FILMS HAVING UNIFORM CONTENT	05803856.3	9/28/2005	1799453	9/5/2012	1799453	6/27/2007
38	HU		Granted - (G)	9/28/2025	MULTI-LAYER FILMS HAVING UNIFORM CONTENT	05803856.3	9/28/2005	1799453	9/5/2012	1799453	6/27/2007
39	IE		Granted - (G)	9/28/2025	MULTI-LAYER FILMS HAVING UNIFORM CONTENT	05803856.3	9/28/2005	1799453	9/5/2012	1799453	6/27/2007
40	CH		Granted - (G)	9/28/2025	MULTI-LAYER FILMS HAVING UNIFORM CONTENT	05803856.3	9/28/2005	1799453	9/5/2012	1799453	6/27/2007
41	GB		Granted - (G)	9/27/2025	MULTI-LAYER FILMS HAVING UNIFORM CONTENT	05803856.3	9/28/2005	1799453	9/5/2012	1799453	6/27/2007
42	JP		Granted - (G)	9/28/2025	MULTI-LAYER FILMS HAVING UNIFORM CONTENT	2007-534705	9/28/2005	5160229	12/21/2012	2011-503994	3/17/2011
43	US		Granted - (G)	1/10/2028	Eddie Water-Soluble Film Containing A Foam Reducing Flaming Agent	11/839,214	9/20/2007	7,972,618*	7/5/2011	2008-0079825	9/20/2007
44	US		Granted - (G)	10/23/2024	PH MODULATED FILMS FOR DELIVERY OF ACTIVES	11/689,013	12/14/2006	7,910,641*	3/22/2011	2007-0148731A1	6/28/2007
45	FR		Granted - (G)	12/14/2026	PH MODULATED FILMS FOR DELIVERY OF ACTIVES	06845545.0	12/14/2006	1988958	12/28/2016		
46	DE		Granted - (G)	12/14/2026	PH MODULATED FILMS FOR DELIVERY OF ACTIVES	06845545.0	12/14/2006	1988958	12/28/2016	1988958	
47	IE		Granted - (G)	12/14/2026	PH MODULATED FILMS FOR DELIVERY OF ACTIVES	06845545.0	12/14/2006	1988958	12/28/2016	1988958	
48	IT		Granted - (G)	12/14/2026	PH MODULATED FILMS FOR DELIVERY OF ACTIVES	06845545.0	12/14/2006	1988958	12/28/2016	1988958	
49	ES		Granted - (G)	12/14/2026	PH MODULATED FILMS FOR DELIVERY OF ACTIVES	06845545.0	12/14/2006	1988958	12/28/2016	1988958	
50	GB		Granted - (G)	12/14/2026	PH MODULATED FILMS FOR DELIVERY OF ACTIVES	06845545.0	12/14/2006	1988958	12/28/2016	1988958	
51	GB		Granted - (G)	12/13/2026	PH MODULATED FILMS FOR DELIVERY OF ACTIVES	06845545.0	12/14/2006	1988958	12/28/2016	1988958	
52	CA		Granted - (G)	1/13/2030	UNIT ASSEMBLY FOR MULTIPLE FILM DOSAGES, Apparatus, and Methods	2,749,564	2/13/2010	2,749,564	11/15/2016	2,749,564	7/22/2010
53	FR		Granted - (G)	1/13/2030	UNIT ASSEMBLY FOR MULTIPLE FILM DOSAGES, Apparatus, and Methods	10701586.9	2/13/2010	2387293	11/16/2016		
54	DE		Granted - (G)	1/13/2030	UNIT ASSEMBLY FOR MULTIPLE FILM DOSAGES, Apparatus, and Methods	10701586.9	2/13/2010	2387293	11/16/2016		
55	IT		Granted - (G)	1/13/2030	UNIT ASSEMBLY FOR MULTIPLE FILM DOSAGES, Apparatus, and Methods	10701586.9	2/13/2010	2387293	11/16/2016		
56	ES		Granted - (G)	1/13/2030	UNIT ASSEMBLY FOR MULTIPLE FILM DOSAGES, Apparatus, and Methods	10701586.9	2/13/2010	2387293	11/16/2016	ES2314513	5/27/2017
57	GB		Granted - (G)	1/13/2030	UNIT ASSEMBLY FOR MULTIPLE FILM DOSAGES, Apparatus, and Methods	10701586.9	2/13/2010	2387293	11/16/2016		

Aggressive Therapeutics - Patents

A	B	C	D	E	F	G	H	I	J	K	L
H&B Ref	Country	Notes	Status	Exp. Date	Title	Appln. No.	Appln. Date	Pat. No.	Issue Date	Publn. No.	Publn. Date
1199-55 RCE II	United States - (US)		Granted - (G)	9/18/2028	Pouch Container	11804,385	5/18/2007	8,353,295*	3/12/2013	2007-045743A1	11/23/2007
1199-56 PCT/China	China P.R. - (CN)		Granted - (G)	6/28/2027**	Pocket Dispenser	200780024332.7	6/29/2007	47002013	4/30/2013	CN101419160A	7/8/2009
1199-56 PCT/FR/DE/JP/US/France	France - (FR)		Granted - (G)	6/29/2027**	Pocket Dispenser	10395880.9	6/29/2007	2301856	7/24/2013	2301856	3/30/2011
1199-56 PCT/FR/DE/JP/US/France	Germany - (DE)		Granted - (G)	6/29/2027**	Pocket Dispenser	10395880.9	6/29/2007	2301856	7/24/2013	2301856	3/30/2011
1199-56 PCT/FR/DE/JP/US/France	Ireland - (IE)		Granted - (G)	6/29/2027**	Pocket Dispenser	10395880.9	6/29/2007	2301856	7/24/2013	2301856	3/30/2011
1199-56 PCT/FR/DE/JP/US/France	Italy - (IT)		Granted - (G)	6/29/2027**	Pocket Dispenser	10395880.9	6/29/2007	2301856	7/24/2013	2301856	3/30/2011
1199-56 PCT/FR/DE/JP/US/France	Spain - (ES)		Granted - (G)	6/29/2027**	Pocket Dispenser	10395880.9	6/29/2007	2301856	7/24/2013	2301856	3/30/2011
1199-56 PCT/FR/DE/JP/US/France	Great Britain - (GB)		Granted - (G)	6/29/2027**	Pocket Dispenser	0796593.7	6/29/2007	2035290	3/9/2011	2035290	3/18/2009
1199-56 PCT/FR/DE/JP/US/France	France - (FR)		Granted - (G)	6/29/2027**	Pocket Dispenser	0796593.7	6/29/2007	2035290	3/9/2011	2035290	3/18/2009
1199-56 PCT/FR/DE/JP/US/France	Germany - (DE)		Granted - (G)	6/29/2027**	Pocket Dispenser	0796593.7	6/29/2007	2035290	3/9/2011	2035290	3/18/2009
1199-56 PCT/FR/DE/JP/US/France	Italy - (IT)		Granted - (G)	6/29/2027**	Pocket Dispenser	0796593.7	6/29/2007	2035290	3/9/2011	2035290	3/18/2009
1199-56 PCT/FR/DE/JP/US/France	Spain - (ES)		Granted - (G)	6/29/2027**	Pocket Dispenser	0796593.7	6/29/2007	2035290	3/9/2011	2035290	3/18/2009
1199-56 PCT/FR/DE/JP/US/France	Switzerland - (CH)		Granted - (G)	6/29/2027**	Pocket Dispenser	0796593.7	6/29/2007	2035290	3/9/2011	2035290	3/18/2009
1199-56 PCT/FR/DE/JP/US/France	Great Britain - (GB)		Granted - (G)	6/29/2027**	Pocket Dispenser	0796593.7	6/29/2007	2035290	3/9/2011	2035290	3/18/2009
1199-64 PCT/FR/DE/JP/US/France	Japan - (JP)		Granted - (G)	7/29/2028	Pocket Structure Such As For A Film Strip	2009-525695	7/29/2008	2010-52018	6/30/2010	534437	8/23/2013
1199-65 PCT/FR/DE/JP/US/France	France - (FR)		Granted - (G)	9/12/2030**	Unit Assembly And Method Of Making Same	1075290.0	9/12/2010	2473420	4/30/2014	2473420	7/11/2012
1199-65 PCT/FR/DE/JP/US/France	Germany - (DE)		Granted - (G)	9/12/2030**	Unit Assembly And Method Of Making Same	1075290.0	9/12/2010	2473420	4/30/2014	2473420	7/11/2012
1199-65 PCT/FR/DE/JP/US/France	Great Britain - (GB)		Granted - (G)	9/12/2030**	Unit Assembly And Method Of Making Same	1075290.0	9/12/2010	2473420	4/30/2014	2473420	7/11/2012
1199-65 RCE II	United States - (US)		Granted - (G)	1/12/2031*	Unit Assembly And Method Of Making Same	12/873,834	9/12/2010	9,150,341	3/10/2011	9,150,341	10/6/2015
1199-70 RCE II	United States - (US)		Granted - (G)	11/22/2037	Packaged Film Dosage Unit Containing A Complexed	11/975,584	3/30/2007	8,568,777*	10/29/2013	2008-0242736	10/7/2008
1199-74 RCE II	United States - (US)		Granted - (G)	10/19/2027	Film Delivery System For Tetrahydrocannabinol	13/588,267	10/19/2007	8,298,583*	10/30/2012	2009-0104270A1	4/23/2009
1199-74 RCE II/CON	United States - (US)		Granted - (G)	10/19/2027	Film Delivery System For Tetrahydrocannabinol	13/588,267	8/17/2012	8,663,666*	3/4/2014	2013-003578A1	7/7/2013
1199-81 PCT/AU/DV/2	Australia - (AU)		Granted - (G)	10/28/2031	PROCESS FOR ANALYZING AND ESTABLISHING DOSE/GE	2020713322	10/28/2011	2020213322	9/23/2022	2020713322	8/27/2020
1199-81 PCT/Canada	Canada - (CA)		Granted - (G)	10/28/2031	PROCESS FOR ANALYZING AND ESTABLISHING DOSE/GE	2,818,931	10/28/2011	2,818,931	12/11/2018	2,818,931	5/3/2012
1199-81 PCT/FR/DE	Germany - (DE)		Granted - (G)	10/28/2031	Process For Analyzing And Establishing Dosage Size In An	11837163.2	10/28/2011	2632440	6/12/2019	2632440	9/4/2013
1199-81 PCT/FR/DE	France - (FR)		Granted - (G)	10/28/2031	Process For Analyzing And Establishing Dosage Size In An	11837163.2	10/28/2011	2632440	6/12/2019	2632440	9/4/2013
1199-81 PCT/FR/DE/UK	Italy - (IT)		Granted - (G)	10/28/2031	Process For Analyzing And Establishing Dosage Size In An	11837163.2	10/28/2011	2632440	6/12/2019	2632440	9/4/2013
1199-81 PCT/FR/DE/UK	Great Britain - (GB)		Granted - (G)	10/27/2031	Process For Analyzing And Establishing Dosage Size In An	50201900070667	10/28/2011	2632440	6/12/2019	2632440	9/4/2013
1199-81 PCT/FR/DE/UK	Japan - (JP)		Granted - (G)	10/28/2031	Process For Analyzing And Establishing Dosage Size In An	2013-536669	10/28/2011	6067827	7/10/2017	2013-542943	9/4/2013
1199-82 A/FR/JP/DV/IV	Australia - (AU)		Granted - (G)	8/5/2030	SUBLINGUAL AND BUCCAL FILM COMPOSITIONS	2020270651	8/5/2010	2020270651	9/8/2022	2020270651	2/25/2020
1199-82 A/FR/JP/DV/IV	China P.R. - (CN)		Granted - (G)	8/5/2030	SUBLINGUAL AND BUCCAL FILM COMPOSITIONS	201060039554.0	8/5/2010	101972016	10/19/2016	CN102481250A	5/30/2012
1199-82 A/FR/JP/DV/IV	Japan - (JP)		Granted - (G)	8/5/2030	Sublingual And Buccal Film Compositions	2012-528388	8/5/2010	5742122	5/29/2015	2013-501718	1/17/2013
1199-83	United States - (US)		Granted - (G)	8/29/2030	Method For Manufacturing Edible Film	12/354,506	12/15/2008	8,282,954*	10/9/2012	2010-0150987	6/17/2010
1199-83 Canada	Canada - (CA)		Granted - (G)	12/14/2029	Method For Manufacturing Edible Film	2,687,017	12/14/2009	2,687,017	4/18/2012	2,687,017	6/15/2010
1199-83 EPO/FRANCE	France - (FR)		Granted - (G)	11/14/2029	METHOD FOR MANUFACTURING EDIBLE FILM	09179800.8	12/14/2009	2165198	9/9/2015		
1199-83 EPO/GERMANY	Germany - (DE)		Granted - (G)	12/14/2029	METHOD FOR MANUFACTURING EDIBLE FILM	09179800.8	12/14/2009	2165198	9/9/2015		
1199-83 EPO/ITALY	Italy - (IT)		Granted - (G)	12/14/2029	METHOD FOR MANUFACTURING EDIBLE FILM	09179800.8	12/14/2009	2165198	9/9/2015		
1199-83 EPO/SPAIN	Spain - (ES)		Granted - (G)	12/14/2029	METHOD FOR MANUFACTURING EDIBLE FILM	09179800.8	12/14/2009	2165198	9/9/2015		
1199-83 EPO/UK	Great Britain - (GB)		Granted - (G)	12/13/2029	METHOD FOR MANUFACTURING EDIBLE FILM	09179800.8	12/14/2009	2165198	9/9/2015		
1199-83 CT/FR/JP	Japan - (JP)		Granted - (G)	12/11/2029	Method For Manufacturing Edible Film	2011-540222	12/11/2009	5719178	3/27/2015	2012-523457	5/31/2012

Asquestive Therapeutics - Patents

A	B	C	D	E	F	G	H	I	J	K	L
HA&I Ref	Country	Notes	Status	Exp. Date	Title	Appln. No.	Appln. Date	Pat. No.	Issue Date	Publn. No.	Publn. Date
1	USA		Granted - (G)	7/13/2030	Stabilized Amine-Containing Compositions	14/635,851	3/27/2015	9,095,977*	8/4/2015	2015-0214106A1	6/25/2015
98	USA		Granted - (G)	2/23/2031	Device And System For Determining Preparing And Administering Therapeutically Effective Doses	2,809,784	2/23/2011	2,809,784	1/30/2018	2,809,784	9/13/2011
99	USA		Granted - (G)	2/23/2031	Device And System For Determining Preparing And Administering Therapeutically Effective Doses	1,174,942.8	2/23/2011	2,598,913	8/29/2019		
100	USA		Granted - (G)	2/23/2031	Device And System For Determining Preparing And Administering Therapeutically Effective Doses	1,174,942.8	2/23/2011	2,598,913	8/29/2019		
101	USA		Granted - (G)	2/23/2031	Device And System For Determining Preparing And Administering Therapeutically Effective Doses	1,174,942.8	2/23/2011	2,598,913	8/29/2019		
102	USA		Granted - (G)	2/23/2031	Device And System For Determining Preparing And Administering Therapeutically Effective Doses	1,174,942.8	2/23/2011	2,598,913	8/29/2019		
103	USA		Granted - (G)	12/19/2031	Method And System For Optimizing Film Production And Minimizing Film Scrap	201,180,837.1	2/16/2011	2,789,536	4/1/2015	2011-0208348A1	8/23/2011
104	USA		Granted - (G)	2/16/2031	Method And System For Optimizing Film Production And Minimizing Film Scrap	201,180,837.1	2/16/2011	2,789,536	4/1/2015	2011-0208348A1	8/23/2011
105	USA		Granted - (G)	2/16/2031	Method And System For Optimizing Film Production And Minimizing Film Scrap	201,180,837.1	2/16/2011	2,789,536	4/1/2015	2011-0208348A1	8/23/2011
106	USA		Granted - (G)	2/16/2031	Method And System For Optimizing Film Production And Minimizing Film Scrap	201,180,837.1	2/16/2011	2,789,536	4/1/2015	2011-0208348A1	8/23/2011
107	USA		Granted - (G)	2/16/2031	Method And System For Optimizing Film Production And Minimizing Film Scrap	201,180,837.1	2/16/2011	2,789,536	4/1/2015	2011-0208348A1	8/23/2011
108	USA		Granted - (G)	2/16/2031	Method And System For Optimizing Film Production And Minimizing Film Scrap	201,180,837.1	2/16/2011	2,789,536	4/1/2015	2011-0208348A1	8/23/2011
109	USA		Granted - (G)	2/16/2031	Method And System For Optimizing Film Production And Minimizing Film Scrap	201,180,837.1	2/16/2011	2,789,536	4/1/2015	2011-0208348A1	8/23/2011
110	USA		Granted - (G)	2/16/2031	Method And System For Optimizing Film Production And Minimizing Film Scrap	201,180,837.1	2/16/2011	2,789,536	4/1/2015	2011-0208348A1	8/23/2011
111	USA		Granted - (G)	2/16/2031	Method And System For Optimizing Film Production And Minimizing Film Scrap	201,180,837.1	2/16/2011	2,789,536	4/1/2015	2011-0208348A1	8/23/2011
112	USA		Granted - (G)	2/16/2031	Method And System For Optimizing Film Production And Minimizing Film Scrap	201,180,837.1	2/16/2011	2,789,536	4/1/2015	2011-0208348A1	8/23/2011
113	USA		Granted - (G)	2/16/2031	Method And System For Optimizing Film Production And Minimizing Film Scrap	201,180,837.1	2/16/2011	2,789,536	4/1/2015	2011-0208348A1	8/23/2011
114	USA		Granted - (G)	2/16/2031	Method And System For Optimizing Film Production And Minimizing Film Scrap	201,180,837.1	2/16/2011	2,789,536	4/1/2015	2011-0208348A1	8/23/2011
115	USA		Granted - (G)	12/18/2031	Method And System For Optimizing Film Production And Minimizing Film Scrap	12/795,152	4/12/2011	11,129,799*	11/5/2013	2011-0158525A1	8/13/2011
116	USA		Granted - (G)	4/5/2032	DUAL LANE COATING	13/086,681	4/12/2011	11,129,799*	9/28/2021	2012-0258859A1	10/18/2012
117	USA		Granted - (G)	4/5/2032	DUAL LANE COATING	2020204212	4/5/2012	2020204212	2/14/2022		
118	USA		Granted - (G)	4/5/2032	DUAL LANE COATING	2,832,715	4/5/2012	2,832,715	5/10/2016	2,832,715	10/18/2012
119	USA		Granted - (G)	4/5/2032	DUAL LANE COATING	1270597.8	4/5/2012	2656850	6/11/2022	2656850	2/19/2014
120	USA		Granted - (G)	4/5/2032	DUAL LANE COATING	1270597.8	4/5/2012	2656850	6/11/2022	2656850	2/19/2014
121	USA		Granted - (G)	4/5/2032	DUAL LANE COATING	1270597.8	4/5/2012	2656850	6/11/2022	2656850	2/19/2014
122	USA		Granted - (G)	4/5/2032	DUAL LANE COATING	1270597.8	4/5/2012	2656850	6/11/2022	2656850	2/19/2014
123	USA		Granted - (G)	4/5/2032	DUAL LANE COATING	1270597.8	4/5/2012	2656850	6/11/2022	2656850	2/19/2014
124	USA		Granted - (G)	4/4/2032	DUAL LANE COATING	1270597.8	4/5/2012	2656850	6/11/2022	2656850	2/19/2014
125	USA		Granted - (G)	4/5/2032	DUAL LANE COATING	2014505193	4/5/2012	5997976	5/20/2016	2014-0158550A1	3/6/2014
126	USA		Granted - (G)	4/5/2032	DUAL LANE COATING	2014505193	4/5/2012	5997976	5/20/2016	2014-0158550A1	3/6/2014
127	USA		Granted - (G)	2/1/2031	Method For Guided Teaming Of Pouch Laminate To Enable Product Removal	2,731,000	2/1/2011	2,731,000	9/19/2017	2,731,000	8/9/2011
128	USA		Granted - (G)	2/8/2031	Method For Guided Teaming Of Pouch Laminate To Enable Product Removal	20111038344A	2/8/2011	20111038344A	8/10/2016	2010-0145780A	8/10/2011
129	USA		Granted - (G)	2/8/2031	Method For Guided Teaming Of Pouch Laminate To Enable Product Removal	2011-040783	2/8/2011	6046877	11/25/2016	2011-040786	8/25/2011

Aggressive Therapeutics - Patents

A	B	C	D	E	F	G	H	I	J	K	L
HA# Ref	Country	Notes	Status	Exp. Date	Title	Appl. No.	Appl. Date	Publ. No.	Issue Date	Publ. No.	Publ. Date
1	USA		Granted - (G)	6/1/2032	USE OF DAMS TO IMPROVE YIELD IN FILM PROCESSING	12/771,883	2/24/2010	8,956,689*	2/17/2015	2011-0206851A1	8/25/2011
130	USA		Granted - (G)	9/21/2031	Method And System For Forming A Pharmaceutical Product Directly Onto A Packaging Surface	201305600	9/21/2011	201305600	9/14/2016	201305600	5/23/2013
131	Canada		Granted - (G)	9/21/2031	Method And System For Forming A Pharmaceutical Product Directly Onto A Packaging Surface	2,815,568	9/21/2011	2,815,568	10/9/2018	2,815,568	3/29/2012
132	Switzerland		Granted - (G)	9/21/2031	Method And System For Forming A Pharmaceutical Product Directly Onto A Packaging Surface	11827397.8	9/21/2011	2618822	2/26/2020	2618822	7/31/2013
133	Germany		Granted - (G)	9/21/2031	Method And System For Forming A Pharmaceutical Product Directly Onto A Packaging Surface	11827397.8	9/21/2011	2618822	2/26/2020	2618822	7/31/2013
134	France		Granted - (G)	9/21/2031	Method And System For Forming A Pharmaceutical Product Directly Onto A Packaging Surface	11827397.8	9/21/2011	2618822	2/26/2020	2618822	7/31/2013
135	Italy		Granted - (G)	9/21/2031	Method And System For Forming A Pharmaceutical Product Directly Onto A Packaging Surface	50202000040800	9/21/2011	2618822	2/26/2020	2618822	7/31/2013
136	Great Britain		Granted - (G)	9/20/2031	Method And System For Forming A Pharmaceutical Product Directly Onto A Packaging Surface	11827397.8	9/21/2011	2618822	2/26/2020	2618822	7/31/2013
137	India		Granted - (G)	9/21/2031	Method And System For Forming A Pharmaceutical Product Directly Onto A Packaging Surface	3552/05A/NP/2013	9/21/2011	905182	1/1/2019		11/14/2014
138	Republic of Korea		Granted - (G)	9/21/2031	Method And System For Forming A Pharmaceutical Product Directly Onto A Packaging Surface	10-2013-7010370	9/21/2011	10-1802553	11/22/2017	10-2013-7010370	2/5/2014
139	United States		Granted - (G)	9/21/2031	Method And System For Forming A Pharmaceutical Product Directly Onto A Packaging Surface	13/236,024	9/21/2011	8,936,825*	1/26/2015	202-0076921A1	3/29/2012
140	United States		Granted - (G)	9/21/2031	Method And System For Forming A Pharmaceutical Product Directly Onto A Packaging Surface	14/597,593	1/25/2015	9,561,191*	2/7/2017	2015-0150825A1	6/4/2015
141	United States		Granted - (G)	8/2/2032	Manufacturing Of Small Film Strips	12/909,895	10/22/2010	9,149,955*	10/6/2015	2012-0100303A1	4/26/2012
142	United States		Granted - (G)	10/22/2030	Manufacturing Of Small Film Strips	14872,672	10/1/2005	10,272,607*	4/30/2019	US 2016-0088826 A1	3/31/2016
143	United States		Granted - (G)	10/22/2030	Manufacturing Of Small Film Strips	16/290,458	3/1/2019	10,940,616*	3/9/2021	2015-0239476	10/31/2019
144	Canada		Granted - (G)	10/21/2031	Manufacturing Of Small Film Strips	3,059,346	10/21/2011	3,049,346	9/12/2021		
145	Canada		Granted - (G)	10/21/2031	Manufacturing Of Small Film Strips	2,815,467	10/21/2011	2,815,467	9/13/2019	2,815,467	4/26/2012
146	China P.R.		Granted - (G)	10/20/2031	Manufacturing Of Small Film Strips	201118059133.5	10/21/2011	21,20118059133.5	3/16/2016	CN15929590A	9/11/2013
147	Germany		Granted - (G)	10/21/2031	Manufacturing Of Small Film Strips	11835203.8	10/21/2011	2629947	4/10/2019	2629947	8/28/2013
148	Germany		Granted - (G)	10/21/2031	Manufacturing Of Small Film Strips	11835203.8	10/21/2011	2629947	4/10/2019	2629947	8/28/2013
149	Spain		Granted - (G)	10/21/2031	Manufacturing Of Small Film Strips	11835203.8	10/21/2011	2629947	4/10/2019	2629947	8/28/2013
150	France		Granted - (G)	10/21/2031	Manufacturing Of Small Film Strips	11835203.8	10/21/2011	2629947	4/10/2019	2629947	8/28/2013
151	Ireland		Granted - (G)	10/21/2031	Manufacturing Of Small Film Strips	11835203.8	10/21/2011	2629947	4/10/2019	2629947	8/28/2013
152	Italy		Granted - (G)	10/21/2031	Manufacturing Of Small Film Strips	50201500094239	10/21/2011	2629947	4/10/2019	2629947	8/28/2013
153	Great Britain		Granted - (G)	10/20/2031	Manufacturing Of Small Film Strips	11835203.8	10/21/2011	2629947	4/10/2019	2629947	8/28/2013
154	Japan		Granted - (G)	10/21/2031	Manufacturing Of Small Film Strips	2013-535110	10/21/2011	597751	7/29/2016	2013-540161	10/31/2013
155	Japan		Granted - (G)	10/21/2031	Manufacturing Of Small Film Strips	2016-54467	10/21/2011	675926	11/17/2020	2016-504381	12/9/2016
156	Republic of Korea		Granted - (G)	10/21/2031	Manufacturing Of Small Film Strips	10-2013-7012954	10/21/2011	10-1937487	1/4/2019	10-2013-7012954	2/25/2014
157	Republic of Korea		Granted - (G)	10/21/2031	Manufacturing Of Small Film Strips	10-2019-7000375	10/21/2011	10-2005223	7/29/2019	10-2005223	7/23/2019
158	United States		Granted - (G)	4/14/2033	Reduction In Stress Cracking Of Films	13/844,423	3/15/2013	9,346,601*	5/24/2016	2014-0262893A1	9/18/2014
159	United States		Granted - (G)	3/15/2033	Reduction In Stress Cracking Of Films	15/180,606	5/20/2016	9,371,173*	9/26/2017	2016-0264330	6/15/2016
160	United States		Granted - (G)	3/15/2033	Reduction In Stress Cracking Of Films	15/710,260	9/20/2017	10,464,739*	11/5/2019	2018-0065767	3/8/2018

Acquestive Therapeutics - Patents

	A	B	C	D	E	F	G	H	I	J	K	L
	App Ref	Country	Notes	Status	Exp. Date	Title	Appl. No.	Appl. Date	Pat. No.	Issue Date	Publn. No.	Publn. Date
198	1199-129 DIV	United States - (US)		Granted - (g)	7/16/2032	Combination Peptide-Nanoparticles And Delivery Systems Incorporating Same	14/048,286	10/8/2013	9,474,687	10/25/2016	2015-009698A1	4/9/2015
199						Holligan LLP Responsible Matters						
200	AQU-027USC1C1	United States - (US)		Granted	8/7/2029	SUBLINGUAL AND BUCCAL FILM COMPOSITIONS	15/069,975	03/14/2016	12,035,889	02/09/2017	10/034,833	07/31/2018
201	AQU-027USC1C1	United States - (US)		Granted	8/7/2029	SUBLINGUAL AND BUCCAL FILM COMPOSITIONS	16/048,243	07/28/2018	19,070,000	03/07/2019	10,821,074	11/03/2020
202	AQU-014US	United States - (US)		Granted - (g)	5/4/2037	ENHANCED DELIVERY EPINEPHRINE COMPOSITIONS	15/587,364	05/04/2017	US 2017-034825A1	12/07/2017	11,191,737	12/07/2021
203	AQU-013USC1P1P	United States - (US)		Granted - (g)	6/18/2038	PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION	15/724,234	10/03/2017	US 2018-0200198 A1	07/19/2018	11,273,131	03/15/2022
204	AQU-14WQ1N	India - (IN)		Granted - (g)	5/4/2037	ENHANCED DELIVERY EPINEPHRINE COMPOSITIONS		11/30/2018	201817045308	03/15/2019	399,590	06/20/2022
205	AQU-14WQ1H	Israel - (IL)		Granted - (g)	5/4/2037	ENHANCED DELIVERY EPINEPHRINE COMPOSITIONS		11/04/2018	IL262750A	12/31/2018	IL262750B	06/01/2022
206	AQU-013WQ1K1	South Korea - (KR)		Granted - (g)	5/22/2037	PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION	10-2018-7035236	12/5/2018	2556696	5/22/2023	10-2019-0005198	1/15/2019

PATENT

REEL: 065446 FRAME: 0515

RECORDED: 11/02/2023